AstraZeneca (AZN) Financial Analysis & Valuation | Quarter Chart

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lok... more
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, an... more

Company facts

Reported company information and share structure.

Company Share structure
Market Cap$262.31BExchangeNYSE
SectorHealthcareIndustryDrug Manufacturers - General
CountryGBCEOPascal Claude Roland Soriot
IPO Date1993-05-12CAGR6.12%
Employees96,100Websitewww.astrazeneca.com
Div. Yield6.84%Payout Ratio46.98%
Buy Back Yield0.26%Total Yield7.1%
AZN chart loading...

Key metrics

Reported fundamentals and market-derived technical indicators.

Fundamentals Technicals
Enterprise Value$304.11BP/E Ratio18.28
Forward P/E19.29PEG Ratio4.8
P/S Ratio1.18P/B Ratio1.52
P/CF Ratio5.03P/FCF Ratio8.15
EPS$9.26EPS Growth 1Y33.07%
EPS Growth 3Y119.87%EPS Growth 5Y119.14%
Revenue Growth 1Y9.93%Gross Margin0.8%
Operating Margin0.24%Profit Margin0.17%
ROE0.22%ROA0.09%
ROCE0.18%Current Ratio0.91
Quick Ratio0.71Cash Ratio0.23
Debt/Equity0.72Interest Coverage8.54
Altman Z Score3.4Piotroski Score8

AstraZeneca (AZN) valuation & financials

AstraZeneca (AZN) has a market capitalization of $262.31B and trades at a price-to-earnings ratio of 18.3. It operates in the Healthcare sector (Drug Manufacturers - General).

AstraZeneca's revenue grew +9.9% over the last year.

AstraZeneca's next earnings report is scheduled for July 27, 2026 before market open; analysts estimate EPS of $2.52.

📈 Analysts estimate AZN EPS of $2.52 for the upcoming quarter. See AstraZeneca revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

AstraZeneca (AZN) — frequently asked questions

When does AstraZeneca (AZN) report earnings next?

AstraZeneca is expected to report earnings on July 27, 2026 before market open. Analysts estimate EPS of $2.52.

What is AstraZeneca's market cap?

AstraZeneca (AZN) has a market capitalization of $262.31B.

What is AZN's P/E ratio?

AstraZeneca trades at a price-to-earnings ratio of 18.3, with trailing twelve-month EPS of $9.26.

How fast is AstraZeneca growing?

AstraZeneca's revenue grew +9.9% over the last year.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)